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Abstract
A 53-year-old male with a history of chronic obstructive pulmonary disease (COPD) on home oxygen presented to the
hospital with worsening shortness of breath plus cough. He
was admitted to the intensive care unit for COPD exacerbation and respiratory failure. A routine evaluation was per-

formed, including a nasopharyngeal swab for a respiratory
viral panel, which was negative. His symptoms improved over
48 hours, after which time a surveillance test for SARS-CoV-2
returned as positive. After clinical improvement, he was discharged to home isolation.

Introduction

ening dyspnea and hypoxia. The patient was recently
treated as an outpatient with oral azithromycin and
prednisone for a suspected COPD exacerbation five
days prior to admission. The patient had symptoms
of purulent phlegm with an oxygen saturation in the
70s at home. In the ED, the patient had a temperature of 97.7°F with a prolonged expiratory phase of
breathing and wheezing as well as diminished breath
sounds. He was noted to have acute on chronic hypoxic/hypercarbic respiratory failure and was admitted to the ICU for further management. His arterial
blood gas showed a pH of 7.27, a partial pressure of
carbon dioxide (pCO2) of 73, a partial pressure of oxygen (pO2) of 185, a bicarbonate of 32.6, a base excess of
3.2 on 60% fraction of inspired oxygen (FiO2) revealing
respiratory acidosis. A rapid influenza screen was negative. His chest x-ray revealed COPD changes and no
acute infiltrate (Figure 1).

An important factor of the current COVID-19 pandemic
is the large number of healthcare workers (HCWs) who
acquire the infection. Initial reports from China indicated that approximately 30% of hospitalized patients
with COVID-19 pneumonia were HCWs.[1] In an attempt to achieve early identification of hospitalized patients with COVID-19, we implemented a surveillance
program in all hospitals in the Louisville area. The goal
of the surveillance was to protect HCWs by identifying
patients with no risk factors for COVID-19 who may
be hospitalized with the disease without being placed
into isolation.[2] Here we present a case of a patient
hospitalized with an acute exacerbation of COPD who
was identified as having COVID-19 due to our active
surveillance program.

Case Report
A 53-year-old male with underlying chronic obstructive pulmonary disease (COPD) and chronic respiratory failure on home oxygen per nasal cannula during
the day and non-invasive positive pressure ventilation
(NIPPV) at night was referred to the emergency department (ED) from the pulmonology clinic for wors-

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/5

After admission to the ICU, the patient was placed on
NIPPV with improvement. Azithromycin and steroids
were again initiated for an acute exacerbation of COPD.
The patient was also given oseltamivir due to a history
of exposure to a contact with influenza virus. He was
stabilized in the ICU and was subsequently transferred
to the medical floor within 24 hours of hospitalization. A respiratory viral/bacterial panel was negative.
1
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Figure 1. The chest radiograph of a patient with an exacerbation of chronic obstructive pulmonary disease who tested positive for SARS-CoV-2.

The patient remained afebrile during his hospitalization. Surveillance testing for COVID-19, caused by the
SARS-CoV-2, collected on the day of admission (two
days earlier), and performed from left over specimen
used to process a respiratory viral panel, was positive.
To that point (early March 2020), no COVID-19 patients
had been identified in the hospital, and he was never
considered a ‘Centers for Disease Control and Prevention (CDC) person under investigation’ according to
the definition at the time (which included international
travel or exposure to a known case). Upon further
questioning, the only place he had been around people other than his spouse was at a large indoor event
a week prior to symptoms starting. He subsequently
decided to leave against medical advice to home isolation.

Discussion
In an effort to protect patients and healthcare workers,
as well as to know for whom PPE should actually be
used, a surveillance study was performed in Louisville,
KY. As one of 13 biosafety laboratories in the country,
the University of Louisville was among the first to receive a sample of the virus from the CDC. With the
virus, a real time PCR (Tecan EVO 100 with multichannel arm, Männedorf, Switzerland) was tested, and val-
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idated allowing Emergency Use Authorization to the
laboratory by the US Food and Drug Administration
(FDA). This report highlights that COPD exacerbations
may be caused by SARS-CoV-2.
Approximately 30 % of patients with COPD exacerbations are due to viruses; influenza, parainfluenza, endemic coronavirus, rhinovirus, adenovirus and respiratory syncytial virus.[3] This report’s patient history
identified one specific social activity, which permitted
him to be exposed to COVID-19 implying that there
was unknown community spread at the time. Pathophysiologically, his chronic lung disease made him
more likely to be susceptible to COVID-19 than an average immunocompetent person like his wife who had
the same exposure. Furthermore, COVID-19 is estimated to have an R0 between two and three [4], while
influenza is approximately 1.3, reflecting the higher
transmission of COVID-19. The combination of these
factors supports his exacerbation of COPD by COVID19. His improvement may have stemmed from the
azithromycin he was given as it has been shown to
be significantly associated with viral load reduction in
COVID-19 patients.[5]
Some studies have explored a relationship between
COVID-19 and COPD exacerbation. First, a study
of 197 patients in China during the early period of
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the pandemic included 55 deaths (28%)—a proportion much higher than the overall pandemic mortality
rate.[6] A total of 3% of the patients had COPD. Only
1% of those who survived had it, while 24% of those
who died had it; (P<0.0001). Surprisingly, a univariate analysis did not find COPD to be a significant risk
factor for death in hospitalized patients.
Second, a meta-analysis of eight studies, including
over 46,000 patients, found respiratory system disease
to be one of the four most common comorbidities in
COVID-19 patients; (2±0, 95% CI 1-3%).[7] Compared
to the other comorbidities, it had the least heterogeneity within and between studies compared to hypertension, diabetes and cardiovascular diseases; meaning
the studies in the meta-analysis were relatively similar regarding the frequency of severe versus non-severe
patients with COPD.

Received: April 2, 2020
Accepted: April 3, 2020

COPD Exacerbation Caused by SARS-CoV-2

Finally, a study of 788 patients with COVID-19 comparing epidemiological characteristics between older and
younger patients (≥ or < 60 years) found that only
2% of elderly patients had COPD while none of the
younger patients had it. COPD was significantly higher
among older adults compared to younger adults with
COVID-19, but overall, it was not common as it ranged
from 2-3%.[8]

Conclusion
In the present case report, a patient had a COPD exacerbation due to COVID-19. The test was performed for
surveillance and not diagnostic purposes, emphasizing the ease of transmissibility, the relevance of surveillance testing, and the importance of understanding the
epidemiology of this novel pathogen.
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